Skip to content

Abliva

Delivering mitochondrial health

  • English
    • English
    • Svenska
  • Abliva
    • This is Abliva
      • Strategy
      • Orphan Drugs
    • Board
    • Team
    • Partners
    • Relevant publications
  • Mitochondrial Disease
    • Primary mitochondrial disease
      • MELAS-MIDD and KSS-CPEO
      • Leigh Syndrome
      • LHON
    • Patients
    • Expanded access policy
  • Research & Development
    • Portfolio
      • KL1333
      • NV354
      • Early programs
    • Clinical trials
      • The FALCON Study
    • Partnering
      • BD Contact
  • Investors
    • Financial reports
      • Annual reports
      • Interim reports
      • Other financial information
    • Financial Calendar
    • Share and owner information
    • Equity research
    • Corporate governance
      • Corporate Governance Reports
      • Annual General Meeting (AGM)
      • Articles of Association
      • Board of Directors
      • Committees
      • Auditor
      • Group management
      • Incentive programs
    • Current general meeting
    • General meetings archive
    • IR contact
  • News
    • Press releases
    • Newsletters
    • Events and Presentations
      • World Mitochondrial Disease Week 2023
    • Company Calendar
    • News subscription
    • Press photos
    • Media contact
    • Privacy policy
  • Contact

Other financial information

Prospekt/Prospectus 2022Download
Prospekt/Prospectus 2021Download
Tilläggsprospekt/Supplementary prospectus 2020Download
Prospekt/Prospectus 2020Download
Prospekt/Prospectus 2019Download
Tilläggsprospekt/Supplementary prospectus 2018Download
Prospekt/Prospectus 2018Download
Prospekt/Prospectus 2016Download
Prospekt/Prospectus 2015Download
Prospekt (svenskt) 2014Download
Prospectus (English) 2014Download
Prospekt/Prospectus 2013Download
Prospekt/Prospectus 2012Download
Prospekt/Prospectus 2010Download
Prospekt/Prospectus 2008Download
Investor relations

Annual reports

Here you'll find all Abliva's annual reports.

Investor relations

Interim reports

Here you'll find all Abliva's interim reports.

STEP 1

The information and documents on this part of Abliva AB’s (publ) (“Abliva“) website may not, according to law and regulations, be made available to certain persons, and consequently, persons whom wish to access the information and documents must inform themselves of and act in accordance with such restrictions. We ask you to read the text below and submit the following confirmation every time you want to enter this website. Your confirmation must be true.

This material does not constitute an offer or invitation to acquire or subscribe for any securities in Abliva in any jurisdiction. This material is not addressed to and is not available to residents or who are located in Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa, the United States or any other country where such act is subject in whole or in part to legal restrictions or requires additional prospectuses, registration or other measures than those arising from Swedish law.

The prospectus and other documents relating to the prospectus may not be distributed in or to a country where the distribution is subject in whole or in part to legal restrictions or requires additional prospectuses, registration or other measures than those arising from Swedish law or contrary to the applicable provisions of such country.

Next

You are not authorized to view the content on this page.

Back to start page

STEP 2

The information on this part of the website does not constitute an offer or invitation to acquire or subscribe for any securities in Abliva in any jurisdiction. No securities issued by Abliva have been or will be registered under the United States Securities Act of 1933 as amended, nor under any corresponding law of any U.S. state. Thus, no securities issued by Abliva are offered, subscribed for, exercised, pledged, sold, resold, allotted, delivered or otherwise transferred, directly or indirectly, in or into the United States, except under an applicable exemption from, or through a transaction not subject to, the registration requirements of the Securities Act and in accordance with the securities laws of the relevant state or other jurisdiction of the United States. The same also applies to any other country where such act is subject in whole or in part to legal restrictions or requires additional prospectuses, registration or other measures than those arising from Swedish law.

By accepting below, I acknowledge that I have read and agreed to be bound by the information, instructions and terms and conditions provided on this part of the website and confirm that I am not in Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa, the United States or in any other country where the distribution of the prospectus or other documents relating to the prospectus is contrary to applicable laws or regulations or requires additional prospectuses, registrations or other measures than the requirements of Swedish law.

ConfirmDecline

Popular shortcuts

Research & Development
Investors
Primary mitochondrial disease
Interim reports

Receive updates straight to your inbox

Choose the categories that you are interested in, and check preferred language.

  1. Startpage
  2. Investors
  3. Other financial information

This is Abliva

  • Strategy
  • Board
  • Team
  • Partners and advisers
  • Relevant publications

Research & Development

  • Research & Development
  • KL1333
  • NV354
  • Early programs
  • Partnering
  • BD Contact

Investors

  • Investors
  • Annual reports
  • Interim reports
  • Other financial information
  • Financial Calendar
  • Share and owner information
  • Equity research
  • Corporate governance
  • Current general meeting
  • General meetings archive
  • IR contact

News

  • Press releases
  • Newsletters
  • Events and Presentations
  • Capital Markets Day 2020
  • Mitochondria Day 2020
  • News subscription
  • Press photos
  • Media contact
  • Privacy policy

Contact

Abliva AB (publ)
Medicon Village
223 81 Lund, Sweden

Phone
+46 (0)46-275 62 20

Generel questions
info@abliva.com

© Copyright 2020 – Abliva AB. All rights reserved. | We use cookies to improve our services | Cookie policy | Privacy policy

Cookies
We serve cookies. If you think that's ok, just click "Accept all". You can also choose what kind of cookies you want by clicking "Settings". Read our cookie policy
Settings Accept all
Cookies
Choose what kind of cookies to accept. Your choice will be saved for one year. Read our cookie policy
  • Necessary
    These cookies are not optional. They are needed for the website to function.
  • Statistics
    In order for us to improve the website's functionality and structure, based on how the website is used.
  • Experience
    In order for our website to perform as well as possible during your visit. If you refuse these cookies, some functionality will disappear from the website.
  • Marketing
    By sharing your interests and behavior as you visit our site, you increase the chance of seeing personalized content and offers.
Save Accept all